Post Cycle Therapy Topics and Facts

[LuvMuhRoids]

Visual Symptoms
Patients should be advised that blurring or other visual symptoms such as spots or flashes (scintillating scotomata) may occasionally occur during therapy with clomiPHENE citrate. These visual symptoms increase in incidence with increasing total dose or therapy duration and generally disappear within a few days or weeks after clomiPHENE citrate therapy is discontinued. However, prolonged visual disturbances have been reported after clomiPHENE citrate therapy has been discontinued and these disturbances may be irreversible. Patients should be warned that these visual symptoms may render such activities as driving a car or operating machinery more hazardous than usual, particularly under conditions of variable lighting. These visual symptoms appear to be due to intensification and prolongation of afterimages. Symptoms often first appear or are accentuated with exposure to a brightly lit environment. While measured visual acuity usually has not been affected, a study patient taking 200 mg clomiPHENE citrate daily developed visual blurring on the 7th day of treatment, which progressed to severe diminution of visual acuity by the 10th day. No other abnormality was found, and the visual acuity returned to normal on the 3rd day after treatment was stopped. Ophthalmologically definable scotomata and retinal cell function(electroretinographic) changes have also been reported. A patient treated during clinical studies developed phosphenes and scotomata during prolonged clomiPHENE citrate administration, which disappeared by the 32nd day after stopping therapy. Postmarketing surveillance of adverse events has also revealed other visual signs and symptoms during clomiPHENE citrate therapy (see ADVERSE REACTIONS). While the etiology of these visual symptoms is not yet understood, patients with any visual symptoms should discontinue treatment and have a completeophthalmological evaluation carried out promptly.






ADVERSE REACTIONS


Clinical Trial Adverse Events

ClomiPHENE citrate, at recommended dosages, is generally well tolerated. Adverse reactions usually have been mild and transient and most have disappeared promptly after treatment has been discontinued. Adverse experiences reported in patients treated with clomiPHENE citrate during clinical studies are


Incidence of Adverse Events in Clinical Studies (Events Greater than 1%) (n = 8029*)

Adverse Event %
Ovarian Enlargement 13.6
Vasomotor Flushes 10.4
Abdominal-Pelvic Discomfort/Distention/Bloating 5.5
Nausea and Vomiting 2.2
Breast Discomfort 2.1
Visual Symptoms 1.5
Blurred vision, lights, floaters, waves, unspecified visual complaints, photophobia, diplopia, scotomata, phosphenes
Headache 1.3
Abnormal Uterine Bleeding 1.3
Intermenstrual spotting, menorrhagia

Includes 498 patients whose reports may have been duplicated in the event totals and could not be distinguished as such. Also, excludes 47 patients who did not report symptom data. The following adverse events have been reported in fewer than 1% of patients in clinical trials: Acute abdomen, appetite increase, constipation, dermatitis or rash, depression, diarrhea, dizziness, fatigue, hair loss/dry hair, increased urinary frequency/volume, insomnia, light-headedness, nervous tension, vaginal dryness, vertigo, weight gain/loss. Patients on prolonged clomiPHENE citrate therapy may show elevated serum levels of desmosterol. This is most likely due to a direct interference with cholesterol synthesis. However, the serum sterols in patients receiving the recommended dose of clomiPHENE citrate are not significantly altered. Ovarian cancer has been infrequently reported in patients who have received fertility drugs. Infertility is a primary risk factor for ovarian cancer; however, epidemiology data suggest that prolonged use of clomiPHENE may increase the risk of a borderline or invasive ovarian tumor.



Dermatologic: Acne, allergic reaction, erythema, erythema multiforme, erythema nodosum, hypertrichosis, pruritus, urticaria.

Central Nervous System: Migraine headache, paresthesia, seizure, stroke, syncope.

Psychiatric: Anxiety, irritability, mood changes, psychosis.
Visual Disorders: Abnormal accommodation, cataract, eye pain, macular edema, optic neuritis, photopsia, posterior vitreous detachment, retinal hemorrhage, retinal thrombosis, retinal vascular spasm, temporary loss of vision.

Cardiovascular: Arrhythmia, chest pain, edema, hypertension, palpitation, phlebitis, pulmonary embolism, shortness of breath, tachycardia, thrombophlebitis.

Musculoskeletal: Arthralgia, back pain, myalgia.

Hepatic: Transaminases increased, hepatitis.

Neoplasms: Liver (hepatic hemangiosarcoma, liver cell adenoma, hepatocellular carcinoma); breast (fibrocystic disease, breast carcinoma); endometrium (endometrial carcinoma); nervous system (astrocytoma, pituitary tumor, prolactinoma, neurofibromatosis, glioblastoma multiforme, brain abscess); ovary (luteoma of pregnancy, dermoid cyst of the ovary, ovarian carcinoma); trophoblastic (hydatiform mole, choriocarcinoma); miscellaneous (melanoma, myeloma, perianal cysts, renal cell carcinoma, Hodgkin’s lymphoma, tongue carcinoma, bladder carcinoma): and neoplasms of offspring (neuroectodermal tumor, thyroid tumor, hepatoblastoma, lymphocytic leukemia).

Genitourinary: Endometriosis, ovarian cyst (ovarian enlargement or cysts could, as such, be complicated by adnexal torsion), ovarian hemorrhage, tubal pregnancy, uterine hemorrhage.

Body as a Whole: Fever, tinnitus, weakness.

Other: Leukocytosis, thyroid disorder.

DRUG ABUSE AND DEPENDENCE: Tolerance, abuse, or dependence with clomiPHENE citrate has not been reported.

OVERDOSAGE Signs and Symptoms: Toxic effects accompanying acute overdosage of clomiPHENE citrate have not been reported. Signs and symptoms of overdosage as a result of the use of more than the recommended dose during clomiPHENE citrate therapy include nausea, vomiting, vasomotor flushes, visual blurring, spots or flashes, scotomata, ovarian enlargement with pelvic or abdominal pain.

Oral LD50:The acute oral LD50 of clomiPHENE citrate is 1700 mg/kg in mice and 5750 mg/kg in rats. The toxic dose in humans is not known.

Dialysis: It is not known if clomiPHENE citrate is dialyzable.



http://www.aidswasting.com/fertility/pdf/serophene.pdf

	CLomid

	finastride

[LuvMuhRoids]

From RXList:

DESCRIPTION

Tamoxifen citrate tablets, a nonsteroidal antiestrogen, are for oral administration. Nolvadex tablets are available as:

10 mg Tablets: Each 10 mg tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.

20 mg Tablets: Each 20 mg tablet contains 30.4 mg of tamoxifen citrate which is equivalent to 20 mg of tamoxifen.

Inactive Ingredients: Carboxymethylcellulose calcium, magnesium stearate, mannitol and starch.

Chemically, tamoxifen is the trans-isomer of a triphenylethylene derivative. The chemical name is (Z)2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N, N-dimethylethanamine 2-hydroxy-1,2,3- propanetricarboxylate (1:1).

Tamoxifen citrate has a molecular weight of 563.62, the pKa' is 8.85, the equilibrium solubility in water at 37°C is 0.5 mg/ml and in 0.02 N HCl at 37°C, it is 0.2 mg/ml.



CLINICAL PHARMACOLOGY

Tamoxifen citrate is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, tamoxifen appears to exert its antitumor effects by binding the estrogen receptors.

In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol for estrogen receptor protein.

Tamoxifen is extensively metabolized after oral administration. Studies in women receiving 20 mg of 14C tamoxifen have shown that approximately 65% of the administered dose is excreted from the body over a period of 2 weeks with fecal excretion as the primary route of elimination. The drug is excreted mainly as polar conjugates, with unchanged drug and unconjugated metabolites accounting for less than 30% of the total fecal radioactivity.

N-desmethyl tamoxifen was the major metabolite found in patients' plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma.

Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/ml (range 35 to 45 ng/ml) occurred approximately 5 hours after dosing. The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life about 5 to 7 days. The average peak plasma concentration for N-desmethyl tamoxifen is 15 ng/ml (range 10 to 20 ng/ml). Chronic administration of 10 mg tamoxifen given twice daily for three months to patients results in average steady-state plasma concentrations of 120 ng/ml (range 67 to 183 ng/ml) for tamoxifen and 336 ng/ml (range 148 to 654 ng/ml) for N-desmethyl tamoxifen. The average steady-state plasma concentrations of tamoxifen and N-desmethyl tamoxifen after administration of 20 mg tamoxifen once daily for 3 months are 122 ng/ml (range 71 to 183 ng/ml) and 353 ng/ml (range 152 to 706 ng/ml), respectively. After initiation of therapy, steady state concentrations for tamoxifen are achieved in about 4 weeks and steady state concentrations for N-desmethyl tamoxifen are achieved in about 8 weeks, suggesting a half-life of approximately 14 days for this metabolite.

In a 3-month crossover steady-state bioavailability study with tamoxifen citrate 10 mg twice a day versus tamoxifen citrate 20 mg given once daily, tamoxifen citrate 20 mg taken once daily has comparable bioavailability to tamoxifen citrate 10 mg taken twice a day.


SIDE EFFECTS

Adverse reactions to tamoxifen citrate are relatively mild and rarely severe enough to require discontinuation of treatment in breast cancer patients.

Continued clinical studies have resulted in further information which better indicates the incidence of adverse reactions with tamoxifen citrate as compared to placebo.

Metastatic Breast Cancer

Increased bone and tumor pain and, also, local disease flare have occurred, which are sometimes associated with a good tumor response. Patients with increased bone pain may require additional analgesics. Patients with soft tissue disease may have sudden increases in the size of preexisting lesions, sometimes associated with marked erythema within and surrounding the lesions and/or the development of new lesions. When they occur, the bone pain or disease flare are seen shortly after starting tamoxifen citrate and generally subside rapidly.

In patients treated with tamoxifen citrate for metastatic breast cancer, the most frequent adverse reaction to tamoxifen citrate is hot flashes.

Other adverse reactions which are seen infrequently are hypercalcemia, peripheral edema, distaste for food, pruritus vulvae, depression, dizziness, light-headedness, headache, hair thinning and/or partial hair loss, and vaginal dryness.

Male Breast Cancer

Tamoxifen citrate is well tolerated in males with breast cancer. Reports from the literature and case reports suggest that the safety profile of tamoxifen citrate in males is similar to that seen in women. Loss of libido and impotence have resulted in discontinuation of tamoxifen therapy in male patients. Also, in oligospermic males treated with tamoxifen, LH, FSH, testosterone and estrogen levels were elevated. No significant clinical changes were reported



DRUG INTERACTIONS

When tamoxifen citrate is used in combination with coumarin-type anticoagulants, a significant increase in anticoagulant effect may occur. Where such coadministration exists, careful monitoring of the patient's prothrombin time is recommended.

In the NSABP P-1 trial, women who required coumarin-type anticoagulants for any reason were ineligible for participation in the trial.

There is an increased risk of thromboembolic events occurring when cytotoxic agents are used in combination with tamoxifen citrate.

Tamoxifen, N-desmethyl tamoxifen and 4-hydroxytamoxifen have been found to be potent inhibitors of hepatic cytochrome p-450 mixed function oxidases. The effect of tamoxifen on metabolism and excretion of other antineoplastic drugs, such as cyclophosphamide and other drugs that require mixed function oxidases for activation, is not known.

One patient receiving tamoxifen citrate with concomitant phenobarbital exhibited a steady state serum level of tamoxifen lower than that observed for other patients (i.e., 26 ng/ml vs. mean value of 122 ng/ml). However, the clinical significance of this finding is not known.

Concomitant bromocriptine therapy has been shown to elevate serum tamoxifen and N-desmethyl tamoxifen.

	Nolva

	finastride

	protein

[LuvMuhRoids]

From RXList:


DESCRIPTION

Clomiphene citrate tablets USP is an orally administered, non steroidal, ovulatory stimulant designated chemically as 2[p-(2- chloro-1,2-diphenylvinyl) phenoxy]] trieth lamine citrate (1:1). It has the molecular formula of C26H28ClNO•C6H8O7 and a molecular weight of 598.09.

Clomiphene citrate is a white to pale yellow, essentially odorless, crystalline powder. It is freely soluble in methanol, soluble in ethanol; slightly soluble in acetone, water, and chloroform; and insoluble in ether. Clomiphene citrate tablets USP is a mixture of two geometric isomers [cis (zuclomiphene) and trans (enclomiphene)] containing between 30% and 50% of the cis-isomer.

Each white scored tablet contains 50 mg clomiphene citrate USP. The tablet also contains the following Inactive Ingredients: corn starch, lactose, magnesium stearate, pregelatinized corn starch, and sucrose



CLINICAL PHARMACOLOGY

Action

Clomiphene citrate tablets USP is a drug of considerable pharmacologic and proper management of the patient, clomiphene citrate tablets USP potency. With careful selection has been demonstrated to be a useful therapy for the anovulatory patient desiring pregnancy.

Clomiphene citrate is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium. vagina, and cervix it may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomiphene crtrate initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event in response to a course of clomiphene therapy, is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle.

Available data suggest that both the estrogenic and antiestrogenic properties of clomiphene may participate in the initiation of ovulation. The two clomiphene isomers have been found to have mixed estrogenic and antrestrogenic effects, which may vary from one species to another. Some data suggest that zuclomiphene has greater estrogenic activity then enclomrphene.

Clomiphene citrate has no apparent progestational, androgenic, or antrandrogenic effects and does not appear to interfere with pituitary-adrenal or pituitary-thyroid function.

Although there is no evidence of a carryover effect of clomiphene citrate tablets USP, spontaneous ovulatory menses have been noted in some patients after clomiphene citrate tablets USP therapy.

Pharmacokinetics

Based on early studies with 14 C-labeled clomiphene citrate, the drug was shown to be readily absorbed orally in humans and excreted principally in the feces. Cumulative urinary and fecal excretion of the 14C averaged about 50% of the oral dose and 37% of an intravenous dose after 5 days. Mean urinary excretion was approximately 8% with fecal excretion of about 42 %.

Some 14C label was still present in the feces 6 weeks after administration Subsequent single-dose studies in normal volunteers showed that zuclomiphene (CIS) has a longer half-life than enclomiphene (trans). Detectable levels of zuclomiphene persisted for longer than a month in these subjects. This may be suggestive of stereo-specific enterohepatic recycling or sequestering of the zuclomiphene. Thus, it is possible that some active drug may remain in the body during early pregnancy in women who conceive in the menstrual cycle during clomiphene citrate tablets USP therapy


SIDE EFFECTS

Clinical Events

Trial Adverse: Clomiphene citrate Tablets USP at recommended dosages, is generally well tolerated. Adverse reactions usually have been mild and transient and most have disappeared promptly after treatment has been discontinued.

The following adverse events have been reported in fewer than 1% of patients in clinical trails: Acute abdomen, appetite increase, constipation, dermatitis or rash, depression, diarrhea, dizziness, fatigue, hair loss/dry hair, increased urinary frequency/volume, insomnia, light-headedness, nervous tension, vaginal dryness, vertigo, weight gain/loss.

Patients on prolonged clomiphene citrate tablets USP therapy may show elevated serum levels of desmoschol. This is most likely due to a direct interference with cholesterols synthesis. However, the serum sterols in patients receiving the recommended dose of clomiphene citrate tablets USP are not significantly altered. Ovarian cancer has been infrequently reported in patients who have received fertility drugs. Infertility is a primary risk factor for ovarian cancer; however, epidemiology data suggest that prolonged use of clomiphene citrate tablets USP may increase the risk of a borderline or invasive ovarian tumor.

Dermatologic: Acne, allergic reaction, erythema, erythema multiforme, erythema nodosum, hypertrichosis, pruritus.

Central Nervous System: Migraine headache, paresthesia, seizure, stroke, syncope.

Psychiatric: Anxiety irritability, mood changes, psychosis.

Visual Disorders: Abnormal accommodation, cataract, eye pain, macular edema, optic neuritis, photopsia, posterior vitreous detachment, retinal hemorrhage, retinal thrombosis, retinal vascular spasm, temporary loss of vision.

Cardiovascular: Arrhythmia, chest pain, edema, hypertension, palpitation, phlebitis, pulmonary embolism, shortness of breath, tachycardia, thrombophlebitis.

Musculoskeletal: Arthralgia, back pain, myalgia.

Hepatic: Transaminases increased, hepatitis.

Neoplasms: Liver (hepatic hemangiosarcoma, liver cell adenoma, hepatocellular carcinoma); breast (fibrocystic disease, breast carcinoma); endometrium (endometrial carcinoma); nervous system (astrocytoma, pituitary tumor, prolactinoma, neurofibromatosis, glioblastoma multiforme, brain abcess); ovary (luteoma of pregnancy, dermoid cyst of the ovary, ovarian carcinoma); trophoblastic (hydatiform mole, choriocarcinoma); miscellaneous (melanoma, myeloma, perianal cysts, renal cell carcinoma, Hodgkin’s lymphoma, tongue carcinoma, bladder carcinoma); and neoplasms of offspring (neuroectodermal tumor, thyroid tumor, hepatoblastoma, lymphocytic leukemia).

Genitourinary: Endometriosis, ovarian cyst (ovarian enlargement or cysts could, as such, be complicated by adnexal torsion), ovarian hemorrhage, tubal pregnancy, uterine hemorrhage Body as a Whole: Fever, tinnitus, weakness.

Other: Leukocytosis, th roid disorder.

Fetal/Neoastal Anomalies


DRUG INTERACTIONS

Drug interactions with clomiphene citrate tablets USP have not been documented.

	CLomid

	finastride

[LuvMuhRoids]

High blood pressure is very common among steroids usage. Check your BP daily and watch your sodium intake or any other BP inducing foods. Try garlic tabs for a quick fix to lowering BP and drink plenty of water.

If you're an adult and your blood pressure is 140/90 or above, you have hypertension and are at risk for heart disease, stroke and other medical problems.

Control Your Risk Factors

Treating high blood pressure almost always includes making lifestyle changes to help to control your risk factors. Controlling risk factors can reduce your risks for heart disease, heart attack and stroke, so it's important to follow your healthcare professional's recommendations carefully. Sometimes, when lifestyle changes aren't enough to control high blood pressure, your doctor will also prescribe medication.

Lose weight if you're overweight
Many people with high blood pressure are also overweight. Fatty tissue requires a lot of blood to feed it. If your doctor recommends that you lose weight, you can work with other healthcare professionals such as registered dietitians, nurses, nurse practitioners, physician's assistants, etc., to get started on the right diet for you. Losing weight will reduce the strain on your heart, and often weight loss will cause your blood pressure to drop. If you're given a diet, follow it closely, including suggestions about reducing how much alcohol you drink. Alcoholic drinks are low in nutrients and high in calories, so if you're trying to lose weight, avoid them.

Get regular physical activity
Lack of physical activity not only may contribute to obesity — it's been proven to increase your risk for heart attack and stroke. Regular physical activity is defined by the American Heart Association as moderate to vigorous exercise 30–60 minutes a day on most days of the week. Physical activity should definitely be a part of your life. Don't be afraid to be active. It's always best to consult your doctor before beginning a new activity program.

Avoid excessive alcohol
Some studies say that drinking more than 3 to 4 ounces of 80-proof alcohol per day will raise blood pressure. A person with high blood pressure can usually drink alcohol in moderation. Limit your alcohol consumption to no more than 1–2 drinks a day. If you're on a weight-reduction diet, remember that alcohol is high in calories.

Stop smoking
Smoking is another key risk factor for heart attack and stroke.

Manage your stress
Relaxing for short periods during your workday, at night and on weekends also may help lower your blood pressure. Stress can lead you to increased smoking, alcohol consumption, overeating and other activities that increase your risk for heart attack and stroke. A great stress-buster is getting the amount of regular physical activity recommended by the American Heart Association.

Decrease sodium (salt) intake
Most Americans eat far more sodium than they need, and less sodium has proven to help lower blood pressure in some people. Your doctor may recommend a low-salt diet if your blood pressure is too high. This means you'll have to avoid salty foods and cut down on how much salt you use in cooking and at the table. Start reading package labels regularly to learn about the sodium content of prepared foods. You'll also discover that herbs and spices give food flavor and avoid the risk of high-sodium intake.

Eat for heart health
The American Heart Association Nutrition Committee recommends that you avoid a high intake of salt and eat enough fruits, vegetables, fat-free and low-fat dairy products. Such diets are rich in potassium, calcium, magnesium and protein, and low in total fat, saturated fat and cholesterol.

Discuss the use of oral contraceptives with your doctor
The incidence of high blood pressure isn’t directly related to a person’s sex. However, doctors usually keep a close watch on a woman’s blood pressure during pregnancy or if she’s taking oral contraceptives. Some women who've never had high blood pressure develop it during pregnancy. Similarly, a woman taking oral contraceptives is more likely to develop high blood pressure if she’s overweight, has had high blood pressure during pregnancy, has a family history of high blood pressure or has mild kidney disease.

Discuss the use of some medications with your doctor
Some other medications also can raise blood pressure and/or interfere with the effectiveness of drugs used against high blood pressure. People with high blood pressure should tell their doctor all of the prescribed and over-the-counter medicines they're taking. These include such drugs as steroids, non-steroidal anti-inflammatory drugs (NSAIDs), nasal decongestants and other cold remedies, diet pills, cyclosporine, erythropoetin, tricyclic antidepressants and monoamine oxidase inhibitors.

Foods to limit or avoid
Frozen or canned foods high in sodium (check labels)
Salted or preserved meats
Salted snack foods

Read labels for a healthy heart
Make reading food labels a habit. They’ll help you choose foods more wisely. Many foods have high levels of saturated fat or hydrogenated fat that can raise your cholesterol. Some may be high in sodium, which can increase blood pressure in some people. Also, watch for these key terms, and know what they mean.

"Free" has the least amount of a nutrient.
"Very Low" and "Low" have a little more nutrient value.
"Reduced" or "Less" always means the food has 25 percent less of that nutrient than the reference (or standard) version of the food.

	protein

	energy

[LuvMuhRoids]

DESCRIPTION:

Tribulus, also known as caltrop and puncture vine, is a natural product isolated from the aerial parts of the plant Tribulus terrestris.

Tribulus was traditionally used by the Greeks as a diuretic, mild laxative, and general tonic. In India, Tribulus is widely recommended in Ayurvedic rejuvenative formulas, particularly in the treatment of sexual dysfunction. In China, Tribulus has been a frequent component of therapy for a variety of disorders affecting the liver, kidneys, and urinary tract. For all its therapeutic and adaptogenic effects, the most common cross-cultural use of Tribulus has been in the treatment of infertility in women, impotence in men, and for increasing the libido of both sexes.

Recently, the fitness enhancing benefits of Tribulus have been brought to the attention of the athletic and body building industries as a result of its use by Eastern European Olympic and World Champion strength and power athletes.

PHYSIOLOGY:

Tribulus terrestris is rich in plant sterols, saponins, flavonoids, alkaloids, unsaturated acids, oils, calcium, phosphorus, iron, and protein. The active components are sterol saponins of furostanol type. The preparation is standardized on the base of the predominating compound protodioscin- not less than 40%.

The effects of Tribulus are the following:

Men: Restores and improves libido sexualis, improves and prolongs the duration of erection. It exerts a stimulating effect on spermatogenesis by increasing the number of spermatozoa and their mobility. It increases the level of testosterone by 33%.

Women: Restores and improves libido sexualis and exerts a slight ovulation effect. It has a favorable influence on vasomotory manifestation during natural menopausal and induced menopausal syndrome, as well as on subjective complaints such as insomnia, general tenseness, irritability, or apathy.

Tribulus also helps reduce cholesterol, lowers high blood pressure, inhibits stress-induced clumping of blood platelets, increases the strength of contraction of the heart muscle, reduces sodium and fluid retention, acts as an anti-urolithiatic (urinary/kidney stone preventing) and litholytic (dissolving), improvement of the profile of red and white blood cells, anti-bacterial, anti-fungal, anti- inflammatory, and analgesic effects.

INDICATIONS:

The suggested use is as follows:

Men: Indicated for impotentic coeundi in Kleinfelter’s Syndrome, varicocele, cryptochism, testicular hypertrophy, and Noonan’s Syndrome. Tribulus is also indicated for sterility based on idiopathic oligoasthenazoospermia sterility and idiopathic azoospermia.

Women: Indicated for endocrinous ovarian sterility, menopausal and induced menopausal syndrome with expressed vasomotory and neurasthenic manifestations. Production of follicle- stimulating hormone and estradiol are increased to stimulate reproduction function.


DIRECTIONS FOR USE:

Dosage and duration of treatment are determined according to the character and the gravity of the symptoms. Most often the dosage is 250-500mg. three times daily with meals.

TOXICITY, CAUTIONS AND CONTRA-INDICATIONS:

No reported toxicity.

REFERENCES:

Dimitrov M., Georgiev P., Vitanov S., Use of tribestan on rams with sexual disorders. "Vet Med Nauki" 24(5) pp. 102-110 1987

Nadkarnia A.K., Indian Materia Medica, Popular Prakashan Private Ltd., Vol 1, pp.1229-1232 1976

Tornova M., Gyulemetovs R., Zarkova S., Tribestan Clinical Studies. pp. 1-27

Wright James E. Ph.D., A Natural Wonder. pp. 140-142, 214 "Muscle and Fitness" September 1996

	protein